by | Mar 9, 2022 | Alhallak, Kinan, Azab, Abdel Kareem
— Disease indication – multiple myeloma
Drug format – antibodies conjugated to nanoparticles for T-cell immunotherapy
Drug class – improved delivery platform
Research stage and Preliminary data:
In vivo:
In vitro proof of concept – in a MM cell line: NanoMuTEs and NanoTC…
by | Feb 16, 2022 | Azab, Abdel Kareem, Federico, Cinzia
— Technology Description
Researchers in Prof. Kareem Azab’s laboratory have developed a liposome drug delivery vehicle to improve efficacy and reduce side effects of multiple myeloma treatment. This system is designed to target compounds to the bone marrow microenvironment (BMME) and simultane…
by | Feb 16, 2022 | Azab, Abdel Kareem, Muz, Barbara
— Researchers in Prof. Abdel Kareem Azab’s laboratory have developed a biologically-targeted cellular drug delivery system to precisely target therapeutic or diagnostic agents to a wide range of cancers. Delivering drugs directly to cancer cells and not to healthy cells could improve outcomes by…
by | Sep 6, 2021 | Azab, Abdel Kareem, Azab, Feda, de la Puente Garcia, Maria del Pilar
— Background
External Beam Radiotherapy (EBR) is commonly used after surgical removal of a tumor (in e.g. a breast-conserving surgery) to control or kill malignant cells. The lack of selectivity due to irradiation of whole or partial organs from outside the body, however, is potentially damaging to t…
by | Jun 26, 2020 | Azab, Abdel Kareem, Federico, Cinzia, Schwarz, Julie, Sun, Jennifer
— Technology Description
Researchers in Prof. Kareem Azab’s laboratory have developed a fast, localized drug delivery system designed to maximize anti-tumor efficacy and reduce side effects by delivering chemotherapy directly to cervical tumors.
The current standard-of-care treatment regimen …